• The Company
    • Who we are
    • Partner Portal
  • Meet the Partners
  • Our Approach
  • Portfolio
    • Current Portfolio
    • Historic Portfolio
  • News
  • Contact Us
The Vertical Group
Investing for Innovation

Silk Road Medical Announces Updated Clinical Data on TCAR Presented at the 44th Annual VEITH Symposium

12/12/2016

 
Via: Yahoo! Finance
SUNNYVALE, Calif., Dec. 12, 2016 /PRNewswire/ -- Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, announced that the 44th annual VEITH Symposium held November 15-19, 2016, in New York City featured several presentations on the company's ENROUTE® Transcarotid Neuroprotection and Stent System, the first and only products specifically designed and indicated for TransCarotid Artery Revascularization (TCAR). Highlights include 1-year data on the pivotal cohort from ROADSTER 1 and the first interim analysis of the 30-day data from the ROADSTER 2 Post Approval Study.

Mahmoud Malas, MD, Director of Endovascular Surgery, Johns Hopkins Bayview Medical Center, and National Co-Principal Investigator for the ROADSTER 1 Long Term Follow-Up Study, presented "Midterm Results of the ROADSTER 1 Pivotal Trial of the Silk Road System for TransCarotid Artery Stent Revascularization (TCAR) In High Risk Patients with Carotid Stenosis." The objective of the ROADSTER 1 Long Term Follow-Up Study is to evaluate the incidence of ipsilateral stroke through one year for patients treated during the pivotal and continued access phases of the ROADSTER 1 Trial. In this ongoing retrospective review of the 141 patients treated in the pivotal phase, Dr. Malas reported outcomes for 87 patients with long term follow-up (median 1.3 years; range 0.5-2.9 years). In this cohort, one patient presented with an ipsilateral stroke following the periprocedural period for an overall one year ipsilateral stroke rate of 1.1%.  Data collection in this cohort continues and will be published upon completion. Dr. Malas concluded that long term outcomes with TCAR are comparable to carotid endarterectomy (CEA) in the standard surgical risk population.

Read More:
 ​http://finance.yahoo.com/news/silk-road-medical-announces-updated-150000931.html

    Archives

    December 2020
    December 2019
    November 2019
    October 2019
    August 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    April 2015
    March 2015
    February 2015
    January 2015
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    February 2014
    January 2014
    December 2013
    October 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013

    RSS Feed

© The Vertical Group - info@vertical-group.com
 PO 218, Berkeley Heights, NJ 07922 | (908) 277-3737
PO 5006, San Mateo, CA  94402 | (650) 566-9060
Picture
Website by Custom Dynamics